Background: Acute Coronary Syndrome (ACS), with or without ST-segment elevation, is a major contributor to global mortality and morbidity. Swift diagnosis and treatment are vital for mitigating cardiac damage and improving long-term outcomes. The 12-lead electrocardiogram (ECG) currently serves as the gold standard for diagnosis in ACS with ST-segment elevation and may support the diagnosis in ACS without ST-segment elevation. However, the growing prevalence of smartwatches enables the acquisition of electrocardiographic data without traditional ECG equipment. While smaller studies support smartwatch ECG use, larger-scale validation within ACS remains lacking. The ACS WATCH II study aims to validate smartwatch ECG recordings for ACS. Methods: The primary objective is to validate smartwatch-obtained electrocardiographic data in patients presenting with ACS. Two cohorts of 120 patients each, presenting ACS with and without ST-segment elevation, will be assessed. Smartwatches will capture recordings of leads I, III, and V2 alongside standard ECGs. These leads, chosen due to a 97% ACS diagnosis sensitivity in previous studies, will undergo blind evaluation by two experienced external assessors against conventional ECG. Additionally, a control sample of 60 healthy individuals will be included. Conclusions: ACS WATCH II pioneers large-scale prospective validation of smartwatch ECG recordings in ACS patients. Additionally, it indirectly validates a swift diagnostic approach using three leads (I, III, and V2). This could expedite time-critical ACS diagnoses and simplify access through smartwatch-based diagnosis.
Background/Objectives: Cardiac allograft vasculopathy (CAV) remains a prevalent and serious long-term complication following orthotopic heart transplantation (OHT), contributing substantially to graft failure and patient mortality. Given the adverse prognostic impact of extensive coronary artery involvement, this study investigates whether myocardial work (MW) indices can serve as a non-invasive tool to detect OHT recipients with a high burden of coronary disease. Methods: In this prospective study, 55 OHT recipients underwent paired evaluations with coronary computed tomography angiography (CCTA) and transthoracic echocardiography (TTE) during routine follow-up. From the echocardiograms, global longitudinal strain (GLS) of the left ventricle (LV) and myocardial work (MW) indices were derived. Patients were classified into two groups according to CCTA findings: those without extensive coronary artery disease (disease affecting fewer than four coronary segments or none, OHT < 4) and those with extensive disease (disease of four or more coronary artery segments, OHT ≥ 4). Results: CCTA revealed extensive coronary disease in 38 OHT recipients, while 17 had involvement of fewer than four segments or none. Between-group comparisons showed significant differences in global wasted work (GWW, energy expended without generating forward flow) and global work efficiency (GWE, the percentage of constructive work relative to total work). Using the Youden Index, the optimal thresholds for identifying extensive disease were GWW > 88 mmHg% and GWE < 94%. Patients exceeding these thresholds had a markedly higher probability of having ≥ 4 affected segments, with ORs of 4.61 for pathological GWW and 3.68 for pathological GWE compared to those with normal values. Conclusions: GWW and GWE demonstrated the strongest performance for identifying OHT recipients with extensive coronary disease. If confirmed in larger cohorts, these indices could offer a practical, non-invasive approach for detecting extensive CAV.
Background/Objectives: Cardiac allograft vasculopathy (CAV) is a major complication following orthotopic heart transplantation (OHT). Graft denervation results in silent ischemia, even when already established, requiring regular screening for early diagnosis. This study explores whether myocardial work (MW) can non-invasively identify OHT patients with obstructive coronary lesions (OCL). Methods: During regular follow-ups, 55 OHT recipients underwent paired, prospective coronary computed tomography angiography (CCTA) and transthoracic echocardiography (TTE) examinations. Additionally, 57 healthy volunteers (HV) provided reference TTE data. Classic echocardiographic parameters, such as left ventricle global longitudinal strain (LV-GLS) and MW indices, were obtained in all individuals. Data from three groups were analyzed: HV, OHT patients without coronary lesions or with <50% lesions on the CCTA (OHT-non-OCL), and OHT patients with ≥50% lesions on the CCTA (OHT-OCL). Results: CCTA identified seven OHT patients with OCL. Significant differences across the groups existed for LV-GLS (OHT-OCL −10.6% CI −14 to −6.8 vs. OHT-non-OCL −15.6% CI −16.5 to −13.4% vs. HV −18% CI −20 to −16, p < 0.01) and global work efficiency (GWE) (OHT-OCL 87% CI 86 to 92 vs. OHT-non-OCL 94% CI 91 to 95 vs. HV 96% CI 95 to 97, p < 0.01). The optimal cut-off values identified using the Youden Index were LV-GLS < −14.4% (AUC 0.80, sensitivity 0.86, specificity 0.71) and GWE < 89% (AUC 0.75, sensitivity 0.71, specificity 0.85). Multivariate analysis showed GWE as the best marker for detecting OCL. Conclusions: GWE is the echocardiographic parameter that best identifies OHT patients that have OCL on CCTA. If validated in larger studies, GWE could become a readily accessible tool for CAV detection.
21 September 2026 in Journal of Physiology and Biochemistry
Background and aims: Albuminuria reflects renal and cardiovascular damage in type 2 diabetes (T2D), but its association is not fully understood. We evaluated the association of macroalbuminuria with cardiac structure and function. Methods: Cross-sectional study of 49 adults with T2D and stage 3 chronic kidney disease (CKD), stratified by macroalbuminuria, and 20 controls. Cardiac assessment included cardiac magnetic resonance (MRI), transthoracic echocardiography (TTE) and nine serum biomarkers, including soluble suppression of tumorigenicity 2 (sST2), a biomarker of myocardial stress and fibrosis. Results: Patients with T2D exhibited higher circulating levels of TIMP-1, MMP-10, neutrophil gelatinase-associated lipocalin (NGAL), NT-proBNP and hs-TnT than controls ( p < 0.05). Among patients with T2D, macroalbuminuria was associated with an additional increase in TIMP-1 ( p < 0.05). Patients with T2D had higher T1 values in MRI scans, particularly those with macroalbuminuria (1051 ms [IQR: 1035–1074] vs. 1009 ms [IQR: 989–1020] in controls, p < 0.001). Although sST2 levels were higher in patients with T2D than in controls and tended to be higher in those with macroalbuminuria, these differences did not reach statistical significance. Nevertheless, higher T1 values were associated with higher sST2 levels, particularly in patients with macroalbuminuria (p for interaction < 0.01). Among patients with macroalbuminuria, high sST2 levels were associated with higher T1 values (1071 ms [IQR: 1052–1087] vs. 1029 ms [IQR: 1013–1043], p < 0.05). Conclusions: In T2D and stage 3 CKD, macroalbuminuria identifies a subgroup with more cardiac structural and functional abnormalities, particularly with elevated sST2. Prospective validation is needed.